Active — Not RecruitingNot Applicable

An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme

Italy100 participantsStarted 2021-05-20

Plain-language summary

Study designobservational, non-interventional, retrospective, multicenter study.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Patients with relapsed or refractory DLBCL who received at least 1 dose of polatuzumab vedotin under the NPP (D.M. 7 Sep 2017) in the period between June 2019 and Feb 2020 in Italy.
✓. Age ≥ 18 years at enrolment.
✓. Written informed consent (if applicable).

overall response rate (ORR)

Timeframe: through study completion, an average of 2 years

NCT IDNCT06734078

SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-12-31